Polygenic Risk Score Predicts Eight Cardiovascular Conditions

Why It Matters

By providing a genetic risk enhancer, the PRS helps clinicians fine‑tune preventive therapy decisions for patients whose conventional scores are ambiguous, potentially reducing cardiovascular events and unnecessary medication.

Key Takeaways

• PRS predicts eight cardiovascular diseases with odds ratios up to 41.0
• Test uses blood or saliva, priced at $255 per assay
• Reclassifies 16‑18% of intermediate‑risk patients, improving treatment decisions
• Adds 0.17 NRI to pooled cohort equations for borderline risk
• Validated in >53,000 biobank participants, showing strong calibration

Pulse Analysis

The rise of polygenic risk scores marks a shift from population‑level guidelines toward individualized cardiovascular prevention. While traditional risk calculators rely on age, cholesterol, and blood pressure, the new PRS incorporates millions of genetic variants to quantify inherited susceptibility. This approach aligns with the American College of Cardiology’s recent endorsement of "risk enhancers," positioning genetics as a complementary tool for patients whose clinical metrics fall into the ambiguous intermediate range.

In the validation cohort of more than 53,000 Mass General Brigham Biobank members, the PRS distinguished high‑risk individuals across eight conditions, delivering odds ratios from 1.7 for thoracic aortic aneurysm to a striking 41.0 for elevated lipoprotein(a). When merged with the pooled cohort equations (PCE) or PREVENT models, net reclassification improvement rose by 0.17‑0.18, meaning a notable fraction of borderline patients were re‑assigned to a more appropriate risk tier. The assay, priced at $255, generates a clear percentile‑based report and can be ordered using either blood or saliva, lowering logistical barriers for primary‑care and preventive cardiology practices.

For providers, the PRS offers a data‑driven lever to decide on statins, antihypertensives, or lifestyle interventions when conventional scores are indecisive. Payers may view the test as a cost‑saving measure if it prevents overtreatment or downstream events. Looking ahead, the developers plan to add oncologic markers, potentially broadening the test’s market appeal. However, clinicians must remain aware of calibration limits—systematic underprediction for some traits—and integrate genetic insights with comprehensive clinical judgment.